Search Result

Results for "

Somatostatin Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Somatostatin Receptor (67) Adenylate Cyclase (2) Amyloid-β (1) Apoptosis (2) Bombesin Receptor (2) CRFR (1) Dopamine Receptor (2) Drug Derivative (1) Endogenous Metabolite (1) Opioid Receptor (2) PACAP Receptor (2) Radionuclide-Drug Conjugates (RDCs) (4) Urotensin Receptor (2)
By Research Areas:	Cancer (24) Cardiovascular Disease (12) Endocrinology (28) Inflammation/Immunology (10) Metabolic Disease (12) Neurological Disease (28)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Click Chemistry

L-817818	Somatostatin Receptor	Endocrinology
L-817818 is a potent and subtype-selective agonist of the **somatostatin receptor*. L-817818 provides a direct approach to defining somatostatin* receptor physiological functions

SRA880	Somatostatin Receptor	Cardiovascular Disease
SRA880 is a non-peptide and selective **somatostatin sst(1) receptor** antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .

Octreotide Maximum Cited Publications 13 Publications Verification SMS 201-995	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the **somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

BIM 23052	Somatostatin Receptor	Neurological Disease
BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying .

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) pamoate is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

SSTR5 antagonist 3	Somatostatin Receptor	Cardiovascular Disease
SSTR5 antagonist 3 (Compound 23) is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with low hERG inhibition. SSTR5 antagonist 3 exhibits potency with IC₅₀ values of 2.8 nM and 1.4 nM in human and mouse, respectively. SSTR5 antagonist 3 can be used for the research of anti-gallstone .

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective **somatostatin receptor type 4 (SST4 receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST4 receptors*, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a **somatostatin receptor antagonist with K_i*s of 6, 17, 66, 1000 and 1000 nM for human somatostatin* receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

Octreotide dimer (parallel)	Somatostatin Receptor	Others
Octreotide dimer parallel is a dimer parallel of Octreotide. Octreotide (HY-P0036) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue .

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

BN-81674	Somatostatin Receptor	Cancer
BN-81674 is a somatostatin analogue and a selective antagonist of the non-peptide human somatostatin sst₃ receptor (K_i=0.92 nM). In addition, BN-81674 reversed the inhibition of cyclic AMP accumulation induced by 1 nM somatostatin through the sst₃ receptor with an IC₅₀ value of 0.84 nM. BN-81674 can be used in cancer research .

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

(2R)-Pasireotide (diaspartate) (2R)-SOM230 (diaspartate)	Endogenous Metabolite	Others
(2R)-Pasireotide ((2R)-SOM230) diaspartate exhibits a 40-fold higher affinity for somatostatin receptor 5 than other somatostatin analogs.

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

L-797591	Somatostatin Receptor	Metabolic Disease
L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist .

Paltusotine 1 Publications Verification CRN00808	Somatostatin Receptor	Endocrinology Cancer
Paltusotine (CRN00808) is an orally active, nonpeptide selective **somatostatin type 2 (SST2) receptor** agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine can be used in research on acromegaly and neuroendocrine tumors .

Paltusotine hydrochloride CRN00808 hydrochloride	Somatostatin Receptor	Neurological Disease Endocrinology
Paltusotine (CRN00808) hydrochloride is an orally active, nonpeptide selective **somatostatin type 2 (SST2) receptor** agonist. Paltusotine hydrochloride has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine hydrochloride can be used in research on acromegaly and neuroendocrine tumors .

PRL 2915	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM .

L-803087	Somatostatin Receptor	Neurological Disease Cancer
L-803087 is a potent and selective **somatostatin sst4 receptor agonist with a K_i** of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

L-803087 TFA	Somatostatin Receptor	Neurological Disease Cancer
L-803087 TFA is a potent and selective **somatostatin sst4 receptor agonist with a K_i** of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .

Branosotine	Somatostatin Receptor	Endocrinology
Branosotine (compound 1-1) is a potent agonist of somatostatin receptor (SSTR2), with the EC₅₀ of ＜0.1 nM .

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

Cyclic SSTR agonist octreotide	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic **Somatostatin Receptor SSTR** agonist .

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

DOTA-LM3 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

DOTA-LM3 TFA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

Pasireotide ditrifluoroacetate 5+ Cited Publications SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .

Pasireotide (diaspartate) SOM230 (diaspartate)	Somatostatin Receptor	Neurological Disease Cancer
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

Pasireotide L-aspartate salt 5+ Cited Publications SOM230 L-aspartate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Zavolosotine	Somatostatin Receptor	Metabolic Disease
Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC₅₀ <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .

SSTR5 antagonist 6	Somatostatin Receptor	Metabolic Disease
SSTR5 antagonist 6 is an orally active somatostatin receptor subtype 5 (SSTR5) antagonist with an IC₅₀ of 24 nM. SSTR5 antagonist 6 can be used in the study of type 2 diabetes .

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and *selective somatostatin* (receptor) subtype 5 (SSTR5)** antagonist and has potential for the research of type 2 diabetes mellitus (T2DM) .

SSTR5 antagonist 1	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC₅₀s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively .

Pasireotide acetate 5+ Cited Publications SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

Cat. No.	Product Name	Target	Research Area

HY-P0036

Octreotide Maximum Cited Publications 13 Publications Verification SMS 201-995	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the **somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

HY-106103A

Seglitide acetate MK 678 acetate; L 36358 acetate	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes .

HY-106103

Seglitide MK-678; L-363586	Somatostatin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
Seglitide (MK-678) is a potent, orally active somatostatin receptor 2 (SSTR₂) agonist, and also a competitive antagonist of SSTR₁₄, SSTR₂₅, and SSTR₂₈. Seglitide has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide can be used for research on diabetes .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-111615A

J-2156 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P10920

DOTAMTATE	Drug Derivative	Cancer
DOTAMTATE is a somatostatin analogue. DOTAMTATE marked ²¹²Pb is promising for research of somatostatin receptor positive neuroendocrine tumors .

HY-P1207

BIM 23052	Somatostatin Receptor	Neurological Disease
BIM 23052 is a somatostatin receptor 5 agonist. BIM 23052 can induce gastric emptying .

HY-P0036B

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Octreotide (SMS 201-995) pamoate is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a **somatostatin receptor antagonist with K_i*s of 6, 17, 66, 1000 and 1000 nM for human somatostatin* receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively) .

HY-P4957

Octreotide dimer (parallel)	Somatostatin Receptor	Others
Octreotide dimer parallel is a dimer parallel of Octreotide. Octreotide (HY-P0036) is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue .

HY-P1201

Cyclosomatostatin 1 Publications Verification	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells .

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties .

HY-P4452

PRL 2915	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM .

HY-P1932

Cortistatin-14	Somatostatin Receptor	Neurological Disease Inflammation/Immunology Endocrinology
Cortistatin-14 is a neuropeptide that shares structural similarities with somatostatin, working by binding to somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) has anticonvulsant, neuroprotective effects, and significant anti-inflammatory properties .

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P4100

Cyclic SSTR agonist octreotide	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic **Somatostatin Receptor SSTR** agonist .

HY-P0024A

Veldoreotide TFA DG3173 TFA; PTR-3173 TFA	Somatostatin Receptor	Endocrinology Cancer
Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P5126

DOTA-LM3 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5126A

DOTA-LM3 TFA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a **somatostatin receptor (SSTR*) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin* antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively .

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P10758

Alkyne-βAG-TOCA	Somatostatin Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-16381A

Pasireotide acetate 5+ Cited Publications SOM230 acetate	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-16381

Pasireotide 5+ Cited Publications SOM230	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .

HY-P1212

Cortistatin 14 (mouse, rat) CST-14 (mouse, rat)	Somatostatin Receptor	Neurological Disease
Cortistatin 14, mouse, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus .

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors .

HY-P1202A

CYN 154806 TFA 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P1202

CYN 154806 1 Publications Verification	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective **somatostatin sst2 receptor antagonist, with pIC₅₀** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively .

HY-P3958

BIM-23027	Somatostatin Receptor Dopamine Receptor	Neurological Disease
BIM-23027 is a selective agonist of sst₂ receptor (EC₅₀=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism .

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM . CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively . CH 275 can be used for the research of alzheimer’s disease .

HY-P2112

DOTA-NOC DOTA-Nal3-octreotide	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Others
DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of **somatostatin receptor** subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-JR11 is a **somatostatin receptor 2 （SSTR2**）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-103277A

BIM 23042 TFA	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042 TFA, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-103277

BIM 23042	Bombesin Receptor	Neurological Disease Metabolic Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca ²⁺ release .

HY-P0221C

PACAP (1-38) free acid	PACAP Receptor	Endocrinology
PACAP (1-38) free acid is an endogenous neuropeptide. PACAP (1-38) free acid potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

HY-P0221B

PACAP (1-38) free acid TFA	PACAP Receptor	Endocrinology
PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .

HY-P2150

Cortistatin-29	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all **somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀** values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-P3618

Cortistatin-29 (reduced)	Somatostatin Receptor	Neurological Disease Inflammation/Immunology
Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all **somatostatin (SS) receptor subtypes with high affinity and shows IC₅₀** values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

Recombinant Proteins Recommended:

Somatostatin Receptor

Cat. No.	Compare	Product Name	Species	Source

HY-P700430

	SSTR2 Protein-VLP, Human (HEK293, His) SSTR2; Somatostatin Receptor 2; Somatostatin Receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
	SSTR2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA, FACS. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

Compare Products

Products

Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample
Size

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81452

	Somatostatin Receptor 2 Antibody (YA1197) SSTR2; Somatostatin Receptor 2; SS 2 R; SS2R; SRIF 1; SS2 R	IHC-P	Human
	Somatostatin Receptor 2 Antibody (YA1197) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1197), targeting Somatostatin Receptor 2. Somatostatin Receptor 2 Antibody (YA1197) can be used for IHC-P experiment in human background.

HY-P83055

	Somatostatin Receptor 5 Antibody (YA2800) SSTR5; SS5R; Sstr5	WB, FC	Human, Mouse, Rat
	Somatostatin Receptor 5 Antibody (YA2800) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2800), targeting Somatostatin Receptor 5, with a predicted molecular weight of 39 kDa (observed band size: 42 kDa). Somatostatin Receptor 5 Antibody (YA2800) can be used for WB, FC experiment in human, mouse, rat background.

HY-P82287

	Somatostatin Receptor 3 Antibody (YA2032) SS3R; SS3-R; SS-3-R; SSR-28	WB	Human
	Somatostatin Receptor 3 Antibody (YA2032) is a non-conjugated IgG antibody, targeting Somatostatin Receptor 3, with a predicted molecular weight of 46 kDa (observed band size: 46 kDa). Somatostatin Receptor 3 Antibody (YA2032) can be used for WB experiment in human background.

Compare Products

Products

Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
Size

Cat. No.	Product Name		Classification

HY-P10758

Alkyne-βAG-TOCA		Alkynes
Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks